Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up
Clicks: 239
ID: 269555
2020
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
8.1
/100
27 views
27 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Baclofen was more effective than placebo in reducing alcohol consumption to low-risk levels. The number of adverse events and more serious adverse events was greater with baclofen than placebo.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (29 words).
Try re-searching for a better abstract.
| Reference Key |
l2020addictiontitrated
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Rigal L;Sidorkiewicz S;Tréluyer JM;Perrodeau E;Le Jeunne C;Porcher R;Jaury P;; |
| Journal | addiction (abingdon, england) |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
research support
non-u.s. gov't
adult
female
male
middle aged
Randomized Controlled Trial
Double-Blind Method
Multicenter Study
follow-up studies
harm reduction
outpatients
baclofen / adverse effects
laurent rigal
stéphanie sidorkiewicz
philippe jaury
pmid:31833590
doi:10.1111/add.14927
pragmatic clinical trial
alcohol drinking / drug therapy
alcohol-related disorders / drug therapy*
baclofen / administration & dosage*
gaba-b receptor agonists / administration & dosage*
gaba-b receptor agonists / adverse effects
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.